These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15760427)

  • 1. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
    Mahamat A; Lavigne JP; Fabbro-Peray P; Kinowski JM; Daurès JP; Sotto A
    Clin Microbiol Infect; 2005 Apr; 11(4):301-6. PubMed ID: 15760427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital.
    Gallini A; Degris E; Desplas M; Bourrel R; Archambaud M; Montastruc JL; Lapeyre-Mestre M; Sommet A
    J Antimicrob Chemother; 2010 Dec; 65(12):2650-7. PubMed ID: 20876240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
    Talon D; Lallemand-De-Conto S; Thouverez M; Bertrand X
    Pathol Biol (Paris); 2004 Mar; 52(2):76-81. PubMed ID: 15001235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of minimum inhibitory concentration values for fluoroquinolones against Escherichia coli causing urinary tract infection in both hospitalized patients and outpatients.
    Tayfour M; Yuce A; Yulug N
    Saudi Med J; 2001 Oct; 22(10):848-51. PubMed ID: 11744939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples.
    Gagliotti C; Nobilio L; Moro ML;
    Clin Microbiol Infect; 2007 Mar; 13(3):328-31. PubMed ID: 17391392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
    Gualco L; Schito AM; Schito GC; Marchese A
    Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
    Chenia HY; Pillay B; Pillay D
    J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients.
    Urbánek K; Kolár M; Strojil J; Koukalová D; Cekanová L; Hejnar P
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):741-5. PubMed ID: 15880441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
    Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
    New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quinolone resistance of Escherichia coli strains isolated from urinary tract infections].
    Agulla A; Montes I
    Enferm Infecc Microbiol Clin; 1994; 12(6):322. PubMed ID: 8080877
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
    Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
    J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antimicrobial susceptibility of Proteus mirabilis urinary tract isolates from 1999 to 2005 at Nîmes University Hospital].
    Mahamat A; Lavigne JP; Bouziges N; Daurès JP; Sotto A
    Pathol Biol (Paris); 2006; 54(8-9):456-61. PubMed ID: 17030456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.
    Usein CR; Tatu-Chiţoiu D; Nica M; Ciontea SA; Palade AM; Condei M; Damian M
    Roum Arch Microbiol Immunol; 2008; 67(1-2):23-9. PubMed ID: 19284163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency of in vitro resistance to fluoroquinolones among clinical isolates of Escherichia coli.
    Poiată A; Bădicuţ I; Grigore L; Buiuc D
    Roum Arch Microbiol Immunol; 2000; 59(1-2):63-9. PubMed ID: 11845477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.